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Abstract: The mechanism of action of elisidepsin (PM02734, Irvalec
®
) is assumed to 
involve membrane permeabilization via attacking lipid rafts and hydroxylated lipids. Here 
we investigate the role of hypoxia in the mechanism of action of elisidepsin. Culturing 
under hypoxic conditions increased the half-maximal inhibitory concentration and decreased 
the drug’s binding to almost all cell lines which was reversed by incubation of cells with  
2-hydroxy palmitic acid. The expression of fatty acid 2-hydroxylase was strongly correlated 
with the efficiency of the drug and inversely correlated with the effect of hypoxia. Number 
and brightness analysis and fluorescence anisotropy experiments showed that hypoxia 
decreased the clustering of lipid rafts and altered the structure of the plasma membrane. 
Although the binding of elisidepsin to the membrane is non-cooperative, its membrane 
permeabilizing effect is characterized by a Hill coefficient of ~3.3. The latter finding is in 
agreement with elisidepsin-induced clusters of lipid raft-anchored GFP visualized by 
confocal microscopy. We propose that the concentration of elisidepsin needs to reach a 
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critical level in the membrane above which elisidepsin induces the disruption of the cell 
membrane. Testing for tumor hypoxia or the density of hydroxylated lipids could be an 
interesting strategy to increase the efficiency of elisidepsin. 
Keywords: elisidepsin; lipid rafts; hydroxylated lipids; fatty acid 2-hydroxylase; 
cooperative binding; membrane permeabilization 
 
1. Introduction 
Although significant progress has been made in the understanding of cancer at the molecular and 
cellular level, the potency of chemotherapy of advanced malignant tumors is still limited and based on 
conventional cytotoxic drugs calling for medications with new mechanism of action [1]. Elisidepsin 
(Irvalec
®
, PM02734) is a synthetic cyclodepsipeptide closely related to Kahalalide F, a natural 
antitumor compound isolated from the Hawaiian marine mollusk Elysia rufescens [2–4]. Preclinically, 
elisidepsin showed antiproliferative activity against a broad spectrum of tumor types [5]. Additionally, 
elisidepsin has been found to have synergistic effects when combined with several different conventional 
chemotherapeutic agents and tyrosine kinase inhibitors in cell lines and mouse xenograft models most 
likely due to its unique mechanism of action [6,7]. In clinical trials, elisidepsin has been shown to have 
a low toxicity profile [8–11] and preliminary assessment of its clinical efficacy showed interesting 
results in different solid tumors [8–12].  
Although ErbB proteins have been implicated as the target of elisidepsin based on weak 
correlations between the drug’s efficiency and ErbB protein expression levels [6,7,13], we have 
refuted this hypothesis by showing that the expression of ErbB1, ErbB2 or ErbB3 proteins have no 
influence on the sensitivity of cell lines to elisidepsin [14]. According to the most widely accepted 
view the primary mechanism of action of elisidepsin involves a direct hit on the membrane by binding 
to lipid rafts [5,14]. Based on experiments with RNA interference-mediated knock-down of fatty acid 
2-hydroxylase (FA2H) and incorporation of exogenous hydroxylated fatty acids, 2-hydroxylated 
sphingolipids have been suggested as the binding site of elisidepsin [15]. It has been postulated that 
elisidepsin binds to hydroxylated lipids in rafts and induces rapid permeabilization of the cell 
membrane [14]. All other effects of the drug, including autophagy [16], necrosis [2,13], disruption of 
lysosomal membranes [17], inhibition of Akt signaling [6,16] and downregulation of ErbB3 expression 
and activation [13,14], are thought to be secondary effects pursuant to the primary hit on the membrane. 
As FA2H, the enzyme thought to be responsible for the generation of the target of elisidepsin [15], 
is oxygen dependent [18,19] and tumor hypoxia is widespread in advanced tumors [20], we have 
decided to investigate its role in the mechanism of action of elisidepsin. In the current paper, we show 
that the sensitivity of cell lines to elisidepsin is proportional to their FA2H level and hypoxia reduces 
the efficiency of the drug. The effect of hypoxia was reversed by the addition of exogenous hydroxylated 
fatty acid. Hypoxia was found to induce changes in the organization of lipid rafts. Our results suggest 
that testing for tumor hypoxia or the density of hydroxylated lipids could potentially increase the 
efficacy of elisidepsin. 
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2. Results 
2.1. The Elisidepsin Sensitivity of Cell Lines is Reduced under Hypoxic Conditions 
We suspected that hypoxia would lead to a diminished synthesis of hydroxylated fatty acids thereby 
reducing the sensitivity of cells to elisidepsin. In order to test the aforementioned assumption different 
cell types were cultured under hypoxic conditions for four days followed by testing their elisidepsin 
sensitivity. Four of the seven investigated cell lines (A431, CHO, HaCaT, HeLa) displayed significantly 
reduced elisidepsin sensitivity while the other three cell types (MCF-7, MDA-MB-453, SKBR-3) were 
resistant to the hypoxia-induced effects (Table 1, Supplementary Figure S1). We reasoned that the 
applied four-day hypoxia may be insufficient to deplete the pool of hydroxylated fatty acids in those 
cells which did not show any change in elisidepsin sensitivity in conditions of reduced oxygen partial 
pressure. Therefore, these cell types were cultured under hypoxic conditions for fourteen days 
followed by testing their elisidepsin sensitivity. Extensive hypoxia slightly increased the IC50 values in 
two of the cell lines (MDA-MB-453, SKBR-3), whereas MCF-7 cells did not show any change under 
these experimental conditions either (Table 1, Supplementary Figure S2). We conclude that hypoxic 
conditions generally lead to diminished sensitivity of cells to elisidepsin.  
Table 1. Sensitivity of cell lines to elisidepsin under hypoxic and normoxic conditions. 
Cells plated in 96-well plates were kept under hypoxic conditions for four days or fourteen 
days followed by elisidepsin treatment. The normoxic control samples were plated one day 
before adding elisidepsin. Both normoxic and hypoxic cells were treated with the drug for 
30 min and allowed to grow for another three days under normoxic and hypoxic conditions. 
The mean IC50 values (±standard error of the mean), determined from three independent 
measurements, are shown in the table. Two-way ANOVA indicated a significant effect of 
hypoxia. Pairwise comparisons between normoxic and hypoxic samples were carried out by 
Tukey’s HSD test. * Asterisks indicate significant difference compared to the normoxic 
values (p < 0.05). Representative dose-response curves from which the IC50 values were 
determined are shown in Supplementary Figures S1 and S2 (n. d. = not determined).  
Cell lines 
IC50 (µM) 
Normoxia 4-day hypoxia 14-day hypoxia 
A431 7.8 ± 0.8 15.4 ± 1.8 * n. d. 
CHO 15 ± 0.8 66 ± 9.3 * n. d. 
HaCaT 7.5 ± 0.9 27.6 ± 4.2 * n. d. 
HeLa 9.1 ± 1.2 16.5 ± 1.7 * n. d. 
MCF-7 1.4 ± 0.3 1.6 ± 0.5 1.7 ± 0.6 
MDA-MB-453 3.6 ± 0.5 3.9 ± 0.7 6.1 ± 0.5 * 
SKBR-3 2.4 ± 0.4 2.3 ± 0.5 5.2 ± 0.2 * 
2.2. The Expression of FA2H Correlates with Elisidepsin Sensitivity in Normoxia and Determines the 
Hypoxia-Induced Increase in the IC50 Values 
We assumed that the complete absence of hypoxia-induced changes in MCF-7 may be the consequence 
of the high expression level of FA2H in these cells. Therefore, we measured the expression level of 
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FA2H by fluorescent staining followed by flow cytometry and correlated the fluorescence intensities 
with the IC50 values measured in normoxic conditions (Figure 1A). The IC50 values and the expression 
level of FA2H showed strong negative correlation (Pearson correlation coefficient: −0.9, 95% confidence 
interval: [−0.96, −0.78], Spearman rank correlation coefficient: −0.86, 95% confidence interval: 
[−0.94, −0.68]; confidence intervals determined by Fisher’s z-transform). These results confirmed 
previous data implying the role of FA2H in determining elisidepsin sensitivity [15]. Next, we compared 
the magnitude of the hypoxia-induced changes to the expression of FA2H (Figure 1B). The analysis 
revealed a strong correlation between the parameters (Pearson correlation coefficient: −0.85, 95% 
confidence interval: [−0.94, −0.66], Spearman rank correlation coefficient: −0.89, 95% confidence 
interval: [−0.96, −0.75], Figure 1B) indicating that high levels of FA2H (indicative of a higher density 
of hydroxylated lipids and thus high cytotoxic activity of elisidepsin) counteracts the effect of hypoxia 
in reducing the sensitivity of cells to the drug. 
Figure 1. FA2H expression determines the sensitivity of cell lines to elisidepsin under 
normoxic conditions and the hypoxia-induced decrease in elisidepsin responsiveness.  
(A) The IC50 values shown in Table 1 were correlated with the expression level of FA2H 
determined by flow cytometry. The means (±standard error of the mean) of three independent 
measurements are shown; (B) The sensitivity of cell lines was determined under normoxic 
and hypoxic conditions as shown in Table 1. The FA2H expression level is plotted as a 
function of the ratio of the IC50 values determined under hypoxic and normoxic conditions. 
The means (±standard error of the mean) of three independent measurements are shown. 
 
In order to show that hypoxia indeed decreases the amount of the product of FA2H we quantified  
2-hydroxy fatty acids in normoxic and hypoxic cells using mass spectrometry. The results showed that 
culturing cells for four days under hypoxic conditions significantly decreased the amount of 2-hydroxylated 
palmitic and stearic acids without significantly affecting their 3-hydroxylated counterparts. Representative 
mass spectrometry tracks are shown in Supplementary Figure S3. 
2.3. 2-Hydroxy Palmitic Acid Reverses the Effect of Hypoxia on Elisidepsin Sensitivity 
Hypoxia may have resulted in a reduced concentration of hydroxylated fatty acids in the plasma 
membrane thereby bringing about the observed reduced efficiency of elisidepsin. In order to test the 
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aforementioned assumption hypoxia-responsive cell lines (A431, CHO, HaCaT, HeLa) were incubated 
in the presence of 2-hydroxy palmitic acid during the last 24 hours of their hypoxic culture followed by 
testing their elisidepsin sensitivity. Hypoxia reduced the efficiency of elisidepsin compared to 
normoxia in this series of experiments as well, while 2-hydroxy palmitic acid reversed the  
hypoxia-induced changes (Table 2, Supplementary Figure S4). We also tested the effect of 3-hydroxy 
palmitic acid on one of the cell lines (A431), but it could not restore the elisidepsin sensitivity of 
hypoxic cells (data not shown). This finding is in accordance with the lack of any significant  
hypoxia-induced change in the levels of 3-hydroxy fatty acids (Supplementary Figure S3). These 
results imply that 3-hydroxy fatty acids do not play an important role in determining elisidepsin 
sensitivity. The fact that methanol, the solvent of the hydroxylated fatty acid, was without any 
significant effect allowed us to conclude that 2-hydroxy palmitic acid abolishes the effect of hypoxia 
on the elisidepsin sensitivity of the cell lines tested. 
Table 2. The effect of hydroxylated palmitic acid on the sensitivity of cell lines to 
elisidepsin in hypoxia. Cells plated in 96-well plates were kept under hypoxic conditions 
for four days. On the third day, they were treated with 100 µM 2-hydroxy palmitic acid  
(2-OH-PA) or its solvent, methanol (MeOH). The normoxic control samples were plated 
one day before adding elisidepsin. Both normoxic and hypoxic cells were treated with the 
drug for 30 min and allowed to grow for another three days under normoxic and hypoxic 
conditions. The mean IC50 values (±standard error of the mean), determined from three 
independent measurements, are shown in the table. Representative dose-response curves 
from which the IC50 values were determined are shown in Supplementary Figure S4. 
Cell lines 
IC50 (µM) 
Normoxia Hypoxia MeOH in hypoxia 2-OH-PA in hypoxia 
A431 9.0 ± 1.7 17.9 ± 2.8 15.6 ± 3.1 7.75 ± 2.0 
CHO 15.6 ± 2.1 34.6 ± 4.7 38.9 ± 5.3 12.3 ± 2.4 
HaCaT 7.6 ± 1.9 18.7 ± 2.5 16.4 ± 2.8 9.5 ± 1.7 
HeLa 9.4 ± 1.0 21.0 ± 3.3 19.0 ± 2.4 10.1 ± 1.8 
2.4. Hypoxia Reduces the Binding of Fluorescent Elisidepsin 
The results presented so far imply that hypoxia leads to diminished binding of elisidepsin to the cell 
membrane. In order to test this idea normoxic and hypoxic A431 cells were incubated in the presence 
of a 1:4 mixture of fluorescent and unlabeled elisidepsin for 2 min followed by removal of unbound 
elisidepsin and confocal microscopy. Dilution of fluorescent and non-fluorescent elisidepsin was 
necessary since it has been shown previously that fluorescent elisidepsin displays vague or no 
fluorescence in the membrane in the absence of unlabeled drug molecules most likely due to the 
formation of clusters and fluorescence quenching [5]. The fluorescence intensity was evaluated in the 
membrane after image segmentation showing a significant reduction in the binding of elisidepsin by 
hypoxia (mean fluorescence intensity in normoxic cells: 79 ± 7, in hypoxic cells: 27 ± 5; p = 0.0002; 
Figure 2A). Since generation of statistically reliable data is more straightforward in flow cytometry, 
we repeated the binding experiment using this technique. Elisidepsin binds to cells and is internalized  
very rapidly [14], therefore fluorescence intensities reported by the flow cytometer do not represent  
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the amount of membrane-bound drug. In order to get around this problem we developed an approach  
to measure the kinetics of binding of fluorescent elisidepsin to the cells (see Supplementary Materials 
and Methods for details). According to this model, the very first part of the curve represents  
membrane-bound elisidepsin without significant contribution from the intracellular space. The slope of 
the initial part of the curve was shown to be proportional to the amount of membrane-bound 
elisidepsin. We compared the uptake of fluorescent elisidepsin in a panel of seven cell lines and 
calculated the fold-reduction induced by hypoxia, which was correlated with the IC50 values observed 
under normoxic conditions (Figure 2B). According to this analysis, hypoxia significantly reduced the 
binding of elisidepsin in those cell lines (A431, CHO, HaCaT, HeLa) whose IC50 values were 
increased under hypoxic conditions. The hypoxia-induced reduction in elisidepsin binding displayed a 
negative correlation with the normoxic IC50 values. We can conclude that the hypoxia-induced 
reduction in elisidepsin sensitivity is caused by reduced binding of the drug to the cell membrane 
under hypoxic conditions. 
Figure 2. The binding of fluorescent elisidepsin is reduced by hypoxia. (A) A431 cells 
kept under hypoxic conditions for four days and their normoxic counterparts were labeled 
with a mixture of elisidepsin containing OregonGreen488-conjugated and unlabeled 
elisidepsin at a molar ratio of 1:4 for two min followed by washing and confocal 
microscopy in five min. The total concentration of elisidepsin was 2 µM, approximately  
5-times smaller than the IC50 of A431 cells. The fluorescence intensity was evaluated in the 
membrane mask determined by manually-seeded watershed transformation after 
subtracting the background determined in a cell-free area of an image; (B) A mixture of 
OregonGreen488-elisidepsin and unlabeled elisidepsin (molar ratio of 1:4) was added to 
the cell suspension and the fluorescence intensity was immediately measured by flow 
cytometry. The total concentration of elisidepsin was 0.5 µM. The slope of cell-bound 
elisidepsin fluorescence intensity as a function of time was estimated in the first ~30 s of 
uptake and the relative reduction of the rate of elisidepsin binding in hypoxia is plotted 
against the IC50 of elisidepsin in normoxia (mean ± standard error of the mean, n = 3). 
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2.5. Elisidepsin Induces Clustering of GPI-Anchored GFP 
All of the current results and evidence presented elsewhere [5,14,15] point at elisidepsin binding to 
the membrane, more specifically to lipid rafts. Therefore, we wanted to investigate the effect of 
elisidepsin on the distribution of lipid rafts in the membrane. To this aim, normoxic and hypoxic A431 
cells were transfected with GPI-anchored GFP (GFP-GPI) followed by elisidepsin treatment in two 
days. The fluorescence of GFP-GPI was unevenly distributed in the membrane of both normoxic and 
hypoxic cells. Elisidepsin treatment induced the formation of bright fluorescent spots in normoxic cells 
while it was without any significant effect in hypoxic cells (Figure 3A). The number of bright fluorescent 
clusters, enumerated by an algorithm, was shown to be significantly higher in elisidepsin-treated 
normoxic cells than under other conditions (two-way ANOVA followed by Tukey’s HSD test, p < 0.01). 
Next, we incubated GFP-GPI-transfected cells in the presence of a fluorescent analog of elisidepsin for 
two min followed by determining the colocalization between the two fluorescent signals. Quantitative 
analysis revealed a strong correlation between the distribution of GFP-GPI and elisidepsin (Figure 3B, 
correlation coefficient = 0.92, 95% confidence interval = [0.78,0.97]). 
Figure 3. Elisidepsin induces the clustering of GPI-anchored GFP. (A) A431 cells were 
kept under hypoxic conditions for two days followed by transfection with GFP-GPI and 
another two days in hypoxia. Control normoxic cells were also transfected with GFP-GPI 
and kept under normoxic conditions for another two days. Confocal microscopic images 
were taken before and after treating the cells with 10 µM elisidepsin for five min.  
The representative images show the membrane adjacent to the coverslip. The insert in  
the lower left panel displays another normoxic cell treated with elisidepsin. Numbers in  
the lower right corner of images represent the mean (±standard error of the mean) number 
of bright fluorescent spots in an image determined from six images; (B) Normoxic A431 
cells transfected with GFP-GPI were labeled with 2 µM elisidepsin containing 
AlexaFluor555-tagged and unlabeled elisidepsin at a molar ratio of 1:4 for two min 
followed by washing twice. Confocal microscopic images taken five min after the washing 
in the GFP and AlexaFluor555 channels and their overlay (green–GFP-GPI;  
red–elisidepsin) are shown in the figure. 
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Since we observed binding of fluorescent elisidepsin at concentrations that did not induce any 
killing, we systematically analyzed the reason for this discrepancy. As the IC50 of fluorescent 
elisidepsin was found to be identical to that of the unconjugated drug within experimental error  
(IC50 of unconjugated drug in A431 cells: 8.8 ± 1.6 µM, fluorescent analog: 9.2 ± 1.8 µM; p > 0.1), we 
compared the concentration dependence of killing and the binding of fluorescent elisidepsin. Killing 
was quantitated as the fraction of propidium iodide-positive cells and binding of fluorescent elisidepsin 
was determined in the membrane. The curves were fitted separately allowing for different half-maximal 
effective or inhibitory concentrations (Kd of binding and IC50 for killing) and Hill coefficients. The Kd 
of binding turned out to be 5.1 µM, whereas the IC50 value was found to be 10.2 µM in agreement with 
previous analyses. As opposed to the binding of fluorescent elisidepsin, which was non-cooperative 
characterized by a Hill coefficient of 1.1, the killing curve was fitted with an equation with a Hill 
coefficient of 3.2 (Figure 4, Supplementary Figure S5). These observations support the assumption that 
elisidepsin undergoes oligomerization in the membrane accompanied by increased clustering of lipid 
raft-associated proteins. 
Figure 4. Difference in the concentration dependence of the binding and killing effect of 
elisidepsin. A431 cells were treated with six different concentrations of elisidepsin 
containing OregonGreen488-elisidepsin and unlabeled elisidepsin mixed at a molar ratio of 
1:4 in the presence of 10 µg/mL propidium iodide. After a 20-min treatment, cells were 
washed and imaged using confocal microscopy. The background-corrected fluorescence 
intensity of membrane-bound elisidepsin (triangles) and the fraction of propidium  
iodide-positive cells (circles) were determined and plotted as a function of elisidepsin 
concentration. Error bars represent the standard error of the mean. The continuous lines are 
fits of the Hill equation to the measurement points. A representative image series is shown in 
Supplementary Figure S5. 
 
2.6. Hypoxia Decreases the Clustering of Lipid Rafts and Induces Changes in the Fluidity and 
Compactness of the Membrane 
Results presented in the previous sections imply that elisidepsin alters the distribution and clustering 
of lipid rafts. In order to test this hypothesis directly we carried out N&B analysis to determine the 
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mean number of GPI-GFP molecules in a cluster. We did not find any significant difference between 
the molecular brightness of GPI-GFP in elisidepsin-treated and control cells implying that the drug did 
not significantly change the average number of GPI-GFP molecules per cluster (Figure 5).  
Hypoxia is expected to decrease the amount of hydroxylated lipids in the membrane thereby 
reducing the number of hydrogen bond donors and acceptors, which may cause measurable changes in 
the clustering of membrane proteins as well as in the fluidity and compactness of the membrane. 
According to N&B analysis carried out on GPI-GFP-transfected normoxic and hypoxic A431 cells the 
molecular brightness of GPI-GFP was indicative of molecular dimers in normoxic cells while a pure 
monomeric population was present in hypoxic cells (Figure 5). Since our previous results pointed at an 
effect of elisidepsin on the structure of the plasma membrane [14], we analyzed whether hypoxia 
modifies the fluidity and compactness of the membrane. Both the viscosity (measured by fluorescence 
anisotropy) and the order (measured by the generalized polarization of Laurdan) of the plasma 
membrane increased in A431 cells cultured under hypoxic conditions for four days, while there was no 
change in these parameters in SKBR-3 cells which did not show any alteration in elisidepsin sensitivity 
after four days of hypoxia either (Supplementary Figure S6). These results imply that hypoxia is associated 
with alterations in the structure of the membrane and the clustering of lipid raft-associated proteins. 
Figure 5. (A) A431 cells were cultured under normoxic conditions or kept in a hypoxic 
atmosphere for four days. Both normoxic and hypoxic cells were transfected with  
GPI-anchored GFP two days before N&B analysis using confocal microscopy. Cells were 
left untreated or incubated in the presence of 10 µg/mL elisidepsin for three min. The 
molecular brightness of GPI-GFP (mean ± standard error of the mean), determined from 
ten cells, is shown in the graph. Asterisks indicate a significant difference between normoxic 
and hypoxic cells (p < 0.05, ANOVA followed by Tukey’s HSD test). The molecular 
brightness of monomeric soluble GFP is shown as a reference; (B) Representative brightness 
curves of pixels in normoxic (blue) and hypoxic (red) cells and in a sample containing 
soluble monomeric GFP (black). 
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3. Discussion 
The results presented in the paper reveal insight into the mechanism of action of elisidepsin which 
can be summarized in the following three points: (a) elisidepsin binds to lipid rafts; (b) elisidepsin 
induces oligomerization of lipid rafts detected in confocal microscopic images and also supported by 
the fact that elisidepsin-induced membrane permeabilization is characterized by a Hill coefficient of  
3–4 while its binding follows a non-cooperative concentration dependence; (c) hypoxia reduces the 
efficiency of elisidepsin by decreasing its binding to the membrane. 
Our results implying the formation of elisidepsin oligomers are in accordance with previous 
fluorescence resonance energy transfer (FRET) experiments [5]. Here we not only present evidence  
for the formation of elisidepsin oligomers, but also for elisidepsin-lipid raft interactions and 
elisidepsin-induced raft clustering. Similar to membrane permeabilization elisidepsin-induced raft 
associations were induced rapidly, within five min of elisidepsin application followed by the 
internalization of lipid rafts in 30 min shown in a previous publication [14]. We failed to detect 
elisidepsin-induced oligomerization of lipid rafts by N&B experiments. We suspect that clusters of 
GPI-anchored, raft-associated proteins occupy only a small fraction of pixels; therefore, their 
contribution to the average molecular brightness is negligible. Since they are not immobile for the 
whole duration of a N&B experiment, they cannot be resolved as pixels with a different molecular 
brightness either. 
Based on the key findings of the paper we propose a model in which elisidepsin binds in a  
non-cooperative fashion to membrane regions enriched in hydroxylated lipids followed by oligomerization 
and membrane permeabilization. It was further assumed that elisidepsin oligomers generate the pores 
responsible for membrane permeabilization and their concentration has to reach a threshold so that 
necrosis takes place. A quantitative elaboration of the model, provided as Supplementary material, 
shows that cooperativity in the dose dependence of cell death is the consequence of attributing membrane 
permeabilization to elisidepsin oligomers [21]. Quantitative predictions of the model which are in 
accordance with our experimental observations are: (a) elisidepsin binds to the membrane at much 
lower concentrations than expected based on the killing curves; (b) membrane permeabilization takes 
place in a narrow concentration range characterized by high cooperativity; (c) the lower the number of 
elisidepsin binding sites (e.g., in hypoxia or in cells with low FA2H expression), the higher the free 
concentration of the drug has to be so that the concentration of elisidepsin oligomers in the membrane 
reaches the critical level; (d) a certain fold-reduction in the number of elisidepsin binding sites results 
in negligible changes in the IC50 if the original number of bindings sites was much higher than the 
critical level, while the same fold-decrease causes substantial increase in the IC50 if the original 
number of binding sites was close to the critical level (Supplementary Figure S7). 
Several lines of evidence support the conclusion that the presence of a membrane environment 
enriched in hydroxylated lipids is necessary for the binding of elisidepsin: (a) FA2H expression level 
correlates with elisidepsin sensitivity; (b) hypoxia reduces the efficiency of elisidepsin which is 
reversed by 2-hydroxy palmitic acid; (c) FA2H expression predicts how much hypoxia increases the 
IC50 of elisidepsin. The last statement can be rationalized by the proposed model since highly 
expressed FA2H generates more “elisidepsin-friendly” plasma membrane requiring more pronounced 
hypoxia to reduce the amount of hydroxylated lipids to a level close to the critical concentration. Our 
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results about the role of FA2H in determining elisidepsin sensitivity are in agreement with previous 
findings [15]. The fact that hydroxylated lipids are primarily present in lipid rafts explains that elisidepsin 
binds to these membrane microdomains [22]. It has recently been shown that FA2H specifically 
generates the R-stereoisomer of fatty acids and only the R-enantiomer is able to reverse the effect of 
FA2H knock-down on membrane viscosity [23]. These findings can be rationalized by the fact that 
(S)-hydroxy fatty acids preferentially form intramolecular hydrogen bonds, while the R-stereoisomer is 
usually involved in intermolecular hydrogen bonds. Therefore, we expect that the (R)-2-hydroxy 
palmitic acid component of the racemic mixture used in our experiments was responsible for restoring 
the effect of elisidepsin in hypoxic cells. 
Hypoxia was found to change the clustering of lipid rafts and the dynamic properties of the cell 
membrane. Although decreased hydrogen bonding resulting from inhibited hydroxylation is expected 
to increase membrane fluidity [22], hypoxia decreased the fluidity of the plasma membrane and 
increased its compactness shown by decreased hydration of Laurdan. These findings are in agreement 
with previous results showing that hypoxia-induced lipid peroxidation results in decreased membrane 
fluidity [24,25]. Decreased clustering of GPI-anchored proteins in hypoxic cells may be the consequence 
of decreased hydrogen bonding or increased viscosity which has been shown to be associated with 
decreased protein clustering [26]. 
Lipid hydroxylation is important for the stability of the cell membrane, lipid rafts, myelin sheaths 
and cornified epithelia [18,22]. The role of FA2H-mediated lipid hydroxylation in maintaining the 
integrity of certain membranes is supported by observations linking the loss of FA2H expression to 
late-onset demyelination [27,28]. Cancer cells display characteristic changes in their fatty acid and 
ganglioside composition [29–31]. An increase in the ratio of saturated/non-saturated fatty acids and 
accumulation of less-complex gangliosides have been observed. In addition, upregulation of FA2H  
in malignant tumors has been reported which may lead to cancer specific cytotoxic effects of 
elisidepsin [18,31]. However, tumor hypoxia is known to decrease the rate of hydroxylation due to 
shortage of oxygen, which acts against the tumor-specificity of elisidepsin by reducing the activity of 
FA2H [31]. The balance between hypoxia-induced increased FA2H expression and its decreased 
catalytic activity due to oxygen shortage is unpredictable, but these parameters must be predictive of 
the sensitivity of tumors to elisidepsin. Although tumor hypoxia is readily detectable in vivo [20,32], 
FA2H expression and the amount of 2-hydroxy fatty acids in the membrane are not amenable to 
clinical investigations and none of these parameters is routinely measured in clinical practice. But 
future clinical trials could define the true potential of this drug with a unique mechanism of action in 
the treatment of human cancer. 
4. Experimental Section  
4.1. Cell Culture and Transfection 
SKBR-3, HeLa, A431, MCF-7, MDA-MB-453 and CHO cells were obtained from the American 
Type Culture Collection (ATCC, Manassas, VA, USA) and grown according to their specifications. 
The immortalized human keratinocyte cell line HaCaT was obtained from the Department of 
Physiology, University of Debrecen, and cultured in DMEM supplemented with 10% FCS and 
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antibiotics. For generating hypoxic conditions cells plated in a flask or chambered coverglass were 
kept in a modular hypoxia chamber (Billups-Rothenberg, Del Mar, CA, USA) flushed with a gas 
mixture containing 1% O2, 5% CO2 and 94% N2 (Linde, Munich, Germany) at a rate of 25 L/min for  
4 min. During 4-day hypoxic culturing the cells were not harvested, but they were harvested and split 
when reaching confluency during 2-week hypoxic culturing. The GFP-GPI plasmid was a kind gift 
from Jennifer Lippincott-Schwartz (NIH, Bethesda, MD, USA). Cells were transfected with the 
Amaxa Nucleofector device (Lonza, Basel, Switzerland). The transfection solution and the program 
were selected according to the “Cell & Transfection Database” of the manufacturer. 
4.2. Antibodies and Chemicals 
The polyclonal antibody against fatty acid 2-hydroxylase (sc161045) and the blocking peptide 
(sc161045-P) were purchased from Santa Cruz (Santa Cruz, CA, USA). 2-hydroxy and 3-hydroxy palmitic 
acid were from Sigma-Aldrich (St. Louis, MO, USA). 4′-(trimethylammonio)-diphenylhexatriene 
(TMA-DPH) and Laurdan (6-dodecanoyl-N,N-dimethyl-2-naphthylamine) were purchased from 
Sigma-Aldrich. Elisidepsin was manufactured by PharmaMar (Madrid, Spain) and dissolved in 
dimethyl sulfoxide at a concentration of 1 mg/mL. 
4.3. Determination of Elisidepsin Sensitivity 
Cells were plated into 96-well plates 24 h before the experiment carried out under normoxic 
conditions or were kept in hypoxia for 96 h. They were treated with a dilution series of elisidepsin for 
30 min in triplicate followed by incubation for 72 h in cell culture medium in a CO2 incubator at 37 °C. 
The viability of cells was determined by measuring the absorbance of WST-1 reagent (Roche 
Diagnostics GmbH, Mannheim, Germany) with an ELISA reader at 450 nm and 620 nm. The IC50 
value was determined by fitting the Hill equation to the measurement data using Matlab (Mathworks 
Inc., Natick, MA, USA). 
4.4. Flow Cytometric Measurement of Fatty Acid 2-Hydroxylase Expression 
Cells were fixed with 3.7% formaldehyde for 30 min on ice followed by washing and labeling with 
a polyclonal antibody against fatty acid 2-hyroxylase (FA2H) dissolved in PBS containing 0.1% BSA 
and 0.1% Triton X-100 for 30 min. Unbound antibodies were removed by washing twice in PBS 
followed by staining with fluorescent secondary antibody. The fluorescence intensity was measured 
with a FacsArray flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). Evaluation was 
performed with FCS Express (De Novo Software, Los Angeles, CA, USA) and the FA2H levels are 
reported as the mean intensity of the sample labeled by the primary and the secondary antibodies 
corrected by subtracting the mean fluorescence intensity of the sample, which was also incubated with 
the blocking peptide. 
4.5. Confocal Microscopy 
An Olympus FV1000 confocal microscope was used to acquire images using a 60× oil immersion 
objective (NA = 1.35). GFP-GPI and OregonGreen488 were excited at 488 nm and their emission was 
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measured above 510 nm when the sample was not labeled by any other dye. It was essential to increase 
the lower cutoff value of the detected emission wavelength range from the default value of 500 nm due 
to strong light scattering from the glass surface when the membrane adjacent to the coverslip was 
imaged. AlexaFluor555 was excited at 543 nm and detected above 555 nm. When GFP-GPI and 
AlexaFluor555 were both present in the sample, the fluorescence of GFP was detected in the spectral 
region of 510–540 nm. For dual imaging of OregonGreen488-elisidepsin and propidium iodide they 
were excited at 488 and 543 nm, respectively. The fluorescence of OregonGreen488 was detected in 
the spectral region of 520 ± 15 nm, whereas propidium iodide was measured at 620 ± 50 nm. Image 
analysis was carried out with DipImage (Delft University of Technology, Delft, The Netherlands) in a 
Matlab environment. For quantitative evaluation of membrane-associated fluorescence intensity the 
cell membrane was identified with the manually-seeded watershed algorithm [33,34] and the mean 
background corrected fluorescence intensity was calculated. The background was measured in a  
cell-free area of images. In order to count the number of localized bright spots images were smoothed 
with a Gauss filter and normalized to their maximum intensity followed by top-hat filtering to remove 
objects larger than the observed spots. Local maxima were identified by the extended maxima transform 
followed by filling the holes and shrinking the spots to single points which were enumerated.  
4.6. Determination of the Binding of Fluorescent Elisidepsin to the Membrane 
For confocal microscopic measurements cells, cultured on chambered coverglass, were labeled with 
a mixture containing fluorescent and unlabeled elisidepsin at a molar ratio of 1:4 for 20 min in the 
presence of 10 µg/mL propidium iodide followed by washing to remove unbound elisidepsin. For flow 
cytometry trypsinized cells were labeled with the same mixture of elisidepsin and measured 
immediately without washing using a FacsAria instrument (Becton Dickinson). Fluorescent elisidepsin 
was prepared by labeling the drug with OregonGreen488 or AlexaFluor555 (both from Invitrogen, 
Carslbad, CA, USA) according to the manufacturer’s specifications. Details of the data analysis are 
described in Supplementary Materials and Methods (Supplementary Figures S8 and S9). 
4.7. Number and Brightness (N&B) Analysis of Cells Transfected by GFP-GPI 
An Olympus FV1000 confocal microscope running in pseudo photon-counting mode was used to 
carry out N&B analysis according to Digman et al. [35]. Live cells were analyzed at room temperature 
in Tyrode’s buffer with 10 mM glucose and 0.1% BSA. Image series of 100 optical slices of the cell 
membrane adjacent to the coverslip were acquired with a pixel size of 82 nm and pixel dwell time of 
10 µs. A single image consisted of 256 × 256 pixels and the central part of images was used for 
analysis to eliminate artifacts arising from scanner speed nonlinearity at the borders. The image stack 
was analyzed with a custom-written Matlab program incorporating functions of the DipImage toolbox. 
The images were first registered (i.e., corrected for lateral shift) followed by calculating the mean and 
variance of every pixel. The apparent brightness was calculated according to the following equation: 
 (1)  
2
1

  B
k
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where 2 and k are the variance and the mean, respectively, of a given pixel. The molecular 
brightness () characterizes the clustering state of a fluorescent molecule by giving the number of 
photons detected from a single diffusing unit during the pixel dwell time. If the image mean decreased 
by more than 10% due to stage shift or photobleaching or if the pixel variance did not converge to zero 
with increasing stack size, the stack was discarded. 
4.8. Measurement of Fluorescence Anisotropy and Generalized Polarization 
Trypsinized cells were resuspended in Hank’s buffer at a concentration of 107/mL and labeled with 
2 µM TMA-DPH or 2.5 µM Laurdan at room temperature for 20 min. After TMA-DPH labeling cells 
were diluted in Hank’s buffer without washing to a concentration of 106/mL for fluorescence 
anisotropy measurements, whereas Laurdan-labeled cells were washed once and resuspended at a 
concentration of 10
6
/mL in Hank’s buffer. Fluorescence measurements were carried out with a 
Fluorolog-3 spectrofluorimeter (Horiba Jobin Yvon, Edison, NJ, USA). The temperature of the cuvette 
holder was adjusted to 37 °C by a circulating water bath. TMA-DPH was excited at 352 nm and its 
emission was measured at 430 nm. The fluorescence anisotropy (r) of TMA-DPH was measured in the 
L-format according to the following formula [36,37]: 
 (2)  
where Ivv and Ivh are the vertical and horizontal components, respectively, of the fluorescence excited 
by vertically polarized light, and G is a correction factor characterizing the different sensitivity of the 
detection system for vertically and horizontally polarized light. 
Laurdan was excited at 350 nm and its emission was detected in the blue range of its emission 
spectrum at 435 nm (Iblue) and at the red edge at 500 nm (Ired). Generalized polarization (GP) of 
Laurdan fluorescence was calculated according to the following formula [38–40]:  
 (3)  
4.9. Determination of 2-Hydroxylated Fatty Acids Using Mass Spectrometry 
We used an existing high performance liquid chromatography/mass spectrometry/mass spectrometry 
(HPLC MS-MS) configuration similar to that already published [41,42]. The separation using HPLC 
was performed in a manner similar to what has been reported previously [41]. For the detection of  
2-hydroxy-palmitate, 3-hydroxy-palmitate and 2-hydroxy-stearate (all chemical reference standards were 
from Sigma-Aldrich) we established a specific MS-MS method using ESI (−) setting with 271 → 271 m/z 
for 2/3-hydroxy-palmitate with a collision energy of 5 V, a dwell time of 0.1 s and 299 → 299 m/z for 
2/3-hydroxy-stearate with a collision energy of 5 V, a dwell time of 0.1 s and a cone voltage of 50 V in 
each case as parameters for multiple reaction monitoring (MRM) measurements. 
  
2
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5. Conclusions  
In summary, we have shown that the necrotic effect of elisidepsin is highly cooperative which is 
most likely explained by membrane permeabilization resulting from elisidepsin oligomers. Moreover, 
we have shown that hypoxia significantly inhibits the anti-tumor effect of elisidepsin in some 
experimental models, apparently by reducing the level of 2-hydroxy lipids in the membrane of tumor 
cells. Our results identify tumor hypoxia and the density of 2-hydroxy lipids as factors predicting 
elisidepsin sensitivity. 
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